A compound of Formula Ila: or a salt, ester, or solvate thereof, wherein each of Ar 1 and Ar 2 independently is unsubstituted C 6 -C 14 aryl, unsubstituted 5 to 14-membered heteroaryl, or C 6 -C 14 aryl or 5 to 14-membered heteroaryl each substituted with one or more substituents selected from the group consisting of halo, CN, NO 2 , NO, N 3 , OR a , NR a R b , C(O)R a , C(O)OR a , C(O)NR a R b , NR b C(O)R a , -S(O) b R a , -S(O) b NR a R b , or R S1 , in which R S1 is C 1 C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 5- or 6-membered heteroaryl, or 4 to 12-membered heterocycloalkyl, b is 0, 1, or 2, each of R a and R b , independently is H or R S2 , and R S2 is C 1 C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 4 to 12-membered heterocycloalkyl, or 5- or 6-membered heteroaryl; and each of R S1 and R S2 , is optionally substituted with one or more substituents selected from the group consisting of halo, OH, oxo, C(O)OH, C(O)O-C 1 C 6 alkyl, CN, C 1 C 6 alkyl, C 1 C 6 alkoxyl, amino, mono-C 1 -C 6 alkylamino, di-C 1 C 6 alkylamino, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 4 to 12-membered heterocycloalkyl, and 5- or 6-membered heteroaryl; and X is S(O) 2 and W 1 is CR 50 R 51 or a single bond; X is C(O) and W 1 is O; or X is C(S) and W 1 is NR 52 ; and each of R 50 , R 51 , and R 52 independently is selected from the group consisting of hydrogen, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 2 -C 6 alkenyl, substituted or unsubstituted C 2 -C 6 alkynyl, substituted or unsubstituted C 6 -C 20 aryl, substituted or unsubstituted C 7 -C 26 arylalkyl, substituted or unsubstituted 5 to 20-membered heteroaryl, and substituted or unsubstituted 6-26 membered heteroarylalkyl; for use in a method of treating or preventing a cell proliferative disorder, wherein the method comprises administering to a subject in need thereof a therapeutically efficient amount of the compound. each of Ar 1 and Ar 2 independently is unsubstituted C 6 -C 14 aryl, unsubstituted 5 to 14-membered heteroaryl, or C 6 -C 14 aryl or 5 to 14-membered heteroaryl each substituted with one or more substituents selected from the group consisting of halo, CN, NO 2 , NO, N 3 , OR a , NR a R b , C(O)R a , C(O)OR a , C(O)NR a R b , NR b C(O)R a , -S(O) b R a , -S(O) b NR a R b , or R S1 , in which R S1 is C 1 C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 5- or 6-membered heteroaryl, or 4 to 12-membered heterocycloalkyl, b is 0, 1, or 2, each of R a and R b , independently is H or R S2 , and R S2 is C 1 C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 4 to 12-membered heterocycloalkyl, or 5- or 6-membered heteroaryl; and each of R S1 and R S2 , is optionally substituted with one or more substituents selected from the group consisting of halo, OH, oxo, C(O)OH, C(O)O-C 1 C 6 alkyl, CN, C 1 C 6 alkyl, C 1 C 6 alkoxyl, amino, mono-C 1 -C 6 alkylamino, di-C 1 C 6 alkylamino, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 4 to 12-membered heterocycloalkyl, and 5- or 6-membered heteroaryl; and X is S(O) 2 and W 1 is CR 50 R 51 or a single bond; X is C(O) and W 1 is O; or X is C(S) and W 1 is NR 52 ; and each of R 50 , R 51 , and R 52 independently is selected from the group consisting of hydrogen, substituted or unsubstituted C 1 -C 6 alkyl, substituted or unsubstituted C 2 -C 6 alkenyl, substituted or unsubstituted C 2 -C 6 alkynyl, substituted or unsubstituted C 6 -C 20 aryl, substituted or unsubstituted C 7 -C 26 arylalkyl, substituted or unsubstituted 5 to 20-membered heteroaryl, and substituted or unsubstituted 6-26 membered heteroarylalkyl; for use in a method of treating or preventing a cell proliferative disorder, wherein the method comprises administering to a subject in need thereof a therapeutically efficient amount of the compound. <EOS>